|
|
Clinical effect of Levetiracetam in the treatment of children with febrile convulsion |
LIAO Yue-juan |
Department of Pediatrics, Guangdong Provincial People′s Hospital, Zhuhai Hospital, Guangzhou 519000, China |
|
|
Abstract Objective To study the clinical effect of Levetiracetam in the treatment of children with febrile convulsion.Methods Ninety-six children with febrile convulsion admitted to our hospital from May 2017 to January 2019 were selected as research objects, and they were divided into control group and observation group according to the random number table method, with 48 cases in each group. The control group was treated routinely, and the observation group was treated with Levetiracetam on the basis of the control group. The clinical efficacy and incidence of adverse reactions in the two groups were compared and analyzed. The symptom relief and levels of brain nerve related factors (neuron-specific enolase [NSE], S-100β protein [S-100β], and brain-derived neurotrophic factor [BDNF]) before and after treatment of the two groups of children were recorded. Results The total effective rate of treatment in the observation group (95.83%) was higher than that in the control group (83.33%), and the antipyretic time was earlier than that in the control group, with statistically significant differences. After treatment, the levels of NSE, S-100β and BDNF in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05).There were no significant differences in the number of fevers and the incidence rate of adverse reactions in the two groups of children (P>0.05). Conclusion Levetiracetam in the treatment of children with febrile convulsion can significantly improve the clinical efficacy, relieve the symptoms of fever in children, greatly improve the level of brain nerve related factors, and ensure the safety of medication, and have a positive effect on the prognosis of children.
|
|
|
|
|
[1] |
王翠玲.热性惊厥的研究进展及合理用药[J].中国临床医生杂志,2017,45(3):18-21.
|
[2] |
施莉,黄盛,李玲,等.791 例小儿癫痫的临床特征及缓解率分析[J].癫痫与神经电生理学杂志,2018,27(5):296-301.
|
[3] |
吴琼,陈凤仪,杨翠.小儿咽扁颗粒治疗上呼吸道感染伴热性惊厥的临床效果[J].中国医药导报,2019,16(11):73-76.
|
[4] |
董玲,李维彬.体质辨识及其在小儿复杂性热性惊厥的临床运用[J].中国中医急症,2019,28(5):917-919.
|
[5] |
王和生.左乙拉西坦治疗小儿热性惊厥临床疗效及对患儿脑神经相关因子和免疫功能的影响[J].空军医学杂志,2018,34(3):170-173.
|
[6] |
中华医学会儿科学分会神经学组.热性惊厥诊断治疗与管理专家共识2016[J].中华儿科杂志,2016,54(10):723-727.
|
[7] |
中华医学会儿科学分会神经学组.热性惊厥诊断治疗与管理专家共识2017 实用版[J].中华实用儿科临床杂志,2017,32(18):1379-1382.
|
[8] |
郭伟中.小儿热性惊厥复发的相关因素分析[J].医学综述,2016,22(15):3070-3072.
|
[9] |
陈强,陈向坚,叶圣.血清S100B 蛋白与血清NSE 联合检测在小儿热性惊厥中的应用[J].中外医学研究,2016,14(24):48-50.
|
[10] |
吴名展,陈伊洁,何素丽,等.左乙拉西坦治疗儿童及青少年癫痫临床分析[J].中国基层医药,2019,26(3):310-314.
|
[11] |
杜雅坤,陈芳,王磊,等.左乙拉西坦对部分性癫痫患儿脑电图和认知功能的影响研究[J].中国全科医学,2019,22(14):1689-1695.
|
[12] |
孟慧琴.小儿热性惊厥用左乙拉西坦治疗后的复发情况及血清学指标变化研究[J].海南医学院学报,2016,22(9):906-909.
|
[13] |
徐晓楠,代珊珊,张妮,等.左乙拉西坦预防小儿热性惊厥复发疗效的Meta 分析[J].临床荟萃,2016,31(7):774-778.
|
[14] |
林泽鸿,蔡晓莹,林广裕.地西泮与左乙拉西坦间歇短程治疗预防热性惊厥发作的研究进展[J].中国小儿急救医学,2018,25(1):56-60.
|
[15] |
赵海丰,吴艳,吕冰聪,等.左乙拉西坦预防小儿热性惊厥复发的临床效果及安全性研究[J].临床药物治疗杂志,2018,16(2):73-76,92.
|
|
|
|